How does axitinib actually work inside the body to fight kidney cancer?
Axitinib blocks three growth-factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) that tumors use to build new blood vessels. This starves the cancer of oxygen and nutrients, slowing or stopping its spread [1].
In clinical trials, axitinib combined with pembrolizumab reduced cancer progression by 37% and improved 5-year survival to 60.7% versus 54.7% with sunitinib alone [1][8]. The drug works by blocking the tumor's ability to recruit new blood vessels—a process called angiogenesis. This mechanism is why axitinib is called a 'tyrosine kinase inhibitor.'
Inside your cells, VEGFR receptors sit on the surface of blood vessel cells. When a tumor sends out VEGF signals, these receptors normally say 'yes, grow new vessels.' Axitinib says 'no'—it locks the receptor and prevents the signal from getting through [1]. Think of it like putting a padlock on the tumor's supply line.
Real-world trade-off: blocking blood vessel growth also affects healthy blood vessels, which is why high blood pressure (40% of patients) and diarrhea (55%) are common [1]. Your oncologist will adjust your dose down from 5 mg to 3 mg or 2 mg twice daily if these side effects become Grade 2 or higher, balancing efficacy against quality of life.
Ask your oncologist: 'If I develop high blood pressure or bad diarrhea, can we lower the dose and still get benefit?' Most patients tolerate 3 mg twice daily well, and the survival benefit remains strong [1].